MARKET

NBP

NBP

NovaBridge Biosciences
NASDAQ
1.580
+0.010
+0.64%
Opening 09:49 06/18 EDT
OPEN
1.580
PREV CLOSE
1.570
HIGH
1.620
LOW
1.565
VOLUME
38.51K
TURNOVER
--
52 WEEK HIGH
6.79
52 WEEK LOW
1.460
MARKET CAP
182.72M
P/E (TTM)
-3.2699
1D
5D
1M
3M
1Y
5Y
1D
NovaBridge Biosciences replaces PwC with Deloitte as auditor
PUBT · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Amkor Technology, Dynatrace, Corvex 
Reuters · 1d ago
NovaBridge Biosciences Shares Climb Premarket After FDA Grants Fast Track Designation
Dow Jones · 2d ago
NovaBridge Wins FDA Fast Track Status For Givastomig In First-Line Gastric Cancer; Stock Up
NASDAQ · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye
Reuters · 2d ago
NovaBridge Says FDA Grants Fast Track Designation To Givastomig Combination For Adv. Gastric Cancer
NASDAQ · 2d ago
BUZZ-NovaBridge rises as stomach cancer drug combo gets FDA fast-track status
Reuters · 2d ago
More
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.

Webull offers NovaBridge Biosciences stock information, including NASDAQ: NBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBP stock methods without spending real money on the virtual paper trading platform.